Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2021-07-20 Director's Dealing
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-20 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-20 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about the IPO of JATT Acquisition Corp, including underwriting agreements, private placement of warrants, amendments to the certificate of incorporation, and other material definitive agreements. It also references the pricing of the IPO and the establishment of a trust account for proceeds. The document does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). Instead, it reports on significant corporate events and transactions related to capital raising and corporate governance changes. This aligns with the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 10,000 characters and contains substantive information, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is CAP with high confidence.
2021-07-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.